A rising number of companies are sponsoring wellness programs to improve employee health and reduce health care costs. This review sought to determine the characteristics and outcomes of employer-sponsored wellness programs and determine possible reasons for their success. METHODS: PubMed, ABI Inform, and Business Source Premier databases and Corporate Wellness Magazine were searched. English-language articles published from 2005-2011 reporting characteristics of employer-sponsored wellness programs and their impact on healthrelated and economic outcomes among US employees were accepted. Animal studies, non-US-based studies, letters, editorials, and economic models were not accepted. Data were abstracted, synthesized, and interpreted. RESULTS: Twenty references were accepted. Wellness interventions were classified into health assessments, lifestyle management, and behavioral health. While improved economic outcomes were reported for companies with wellness programs (ie, total health care costs, return on investment, absenteeism, productivity, workers' compensation, utilization) as well as decreased health risks, cause-and-effect relationships could not be determined. Fourteen accepted articles were published in magazines and four in newspapers. Only three were published in peer-reviewed journals and those articles were the only ones to report a study design: 2 were described as quasi-experimental and the third a survey. Most articles described one company's wellness programs and outcomes, with some reporting changes over time. Some of the reported wellness programs were not described in full detail. Multiple types of outcomes were described across accepted articles, which precluded comparisons of an individual outcome across studies. Some articles described multiple interventions, making it difficult to assess benefits from individual interventions. CONCLUSIONS: While employer-sponsored wellness programs are being reported along with improved outcomes, there are limited definitive data on a cause-and-effect relationship. Further research, of a high methodological caliber, is needed to support informed decisions. Specifically, randomized trials and economic analyses would empower employers with the information needed to implement successful wellness programs.
OBJECTIVES:
Choice of comparator(s) is a critical design parameter for any health economic evaluation (HE) . HE guidelines may differ in their recommendations on this issue. We reviewed all accessible HE guidelines to identify shared themes and differences within their recommendations on comparator selection. METHODS: We systematically searched PubMed/Medline, the Centre for Reviews and Dissemination, the EQUATOR network, and websites of health technology assessment agencies and healthcare coverage decisionmaking bodies for publicly accessible HE guidelines. Guidelines were classified as jurisdictional mandatory or non-mandatory or as general. Following review and parsing, data was extracted into a template and recommendations were coded under common, non-mutually exclusive themes. Both qualitative and quantitative analyses were performed. RESULTS: Seventyfour HE guidelines were identified and reviewed, of which 74% mentioned the issue of comparators: 96% of jurisdictional mandatory, 91% of jurisdictional non-mandatory and 58% of general guidelines. The most frequent recommendations with respect to comparator selection were to use the most common treatment (70.9% of all guidelines), to include "no intervention" when appropriate (41.8%), and to use best practice (e.g., guideline-or specialist recommended treatment) as comparator (29.1%). Other recommendations were to compare with the treatment most likely to be replaced (18.2%), to use all alternative treatments (16.4%), and the least costly treatment (14.5%). Almost half (45.5%) of guidelines specified justification of choice of comparator and 21.8% detailed description of all comparators. Mandatory jurisdictional guidelines were more likely than general guidelines to specify most common treatment (86.4% vs. 47.8%, Pϭ0.01 Fisher's exact test), whereas general guidelines were more likely to recommend all alternative forms of therapy (30.4% vs. 4.5%, PϽ0.05). CONCLUSIONS: Although there are common themes among guidelines on comparator selection, differences exist of which model developers need to be aware. OBJECTIVES: Post-approval product research in the form of observational study is increasingly prominent. Observational studies inform real-world safety and effectiveness. Lack of specific regulatory requirements or guidances for source data verification (SDV) in these studies, however, leaves sponsors and partner CROs to determine the level of SDV necessary to ensure quality. A literature review was performed to determine the level of SDV in practice in published observational studies. METHODS: Google Scholar and Pubmed searches were used to retrieve relevant publications. The term 'source data verification' was used in combination with the terms 'observational study' and 'non-interventional study'. Articles readily available in full text were included for analysis. The methods sections were screened to determine the level of SDV applied. If multiple publications referred to a single study or registry, only one representative publication was selected for inclusion. RESULTS: Of the observational studies included, 37 studies mentioned SDV in their methods section. Of these, 16 (43%) did not further specify the level of SDV. In the remaining 21 studies, SDV ranged from 0 to 100%, with a median of 10%. Subject numbers in these 21 studies ranged between 135 and 19,870 (median: 864.) These studies were mainly prospective (14/21) and were conducted in the EU (16/ 21), China (1/21), Australia (1/21), the Philippines (1/21) and worldwide (2/21). The majority (16/21) of the studies were reported to be funded by the pharmaceutical industry. Generally, studies larger than 1000 subjects sought to verify data sources for only 10% of their population. CONCLUSIONS: The level of SDV is not routinely specified in the methods section of observational study publications. In those publications that did elaborate on study quality, the level of SDV ranges between 0% and 100%, with large (nϾ1000 subjects) observational studies restricting the level of SDV to a maximum of 10%.
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PRM54 A CONCEPTUAL ANALYSIS OF WHEN MEDICAL EXPENDITURE PANEL SURVEY (MEPS) MEETS COST OF ILLNESS (COI) -ARE THEY A MATCH?
Coughlan D, Frick KD Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA OBJECTIVES: MEPS has been used as a data source for many direct medical expenditures (DME)/COI type studies. The objective of this conceptual analysis is to review the literature & evaluate the 4 main COI type studies with reference to patients with head and neck cancer (HNC) using the MEPS data source. METHODS: The 4 main COI methods are 1) Sum_All Medical; 2) Sum_Diagnosis Specific; and 3) Matched Control (iv) Regression. Without a comparison group, analysts use a total cost approach. With a comparison group, an incremental cost approach is most often reported. ISPOR does not have standard guidelines in reporting COI studies; analysts often vary in their perspective, but should always make reference to medical costs, morbidity & mortality costs, transportation/nonmedical costs and productivity losses in their analysis. RESULTS: A review of recent COI type papers (nϭ10) that have used MEPS shows that analysts report findings based on usually 1 COI method. Only 2 studies (COPD & Diabetes) reported both total and incremental cost approaches in their analysis. Four studies merged condition, event and consolidated year files, which allows diagnosis specific estimates to be produced. As a conceptual analysis, HNC is used to illustrate that MEPS facilitates analysts to use the 4 main COI methods especially if DME is the outcome of interest. CONCLUSIONS: MEPS is a valuable and utilized national resource. It is possible that "good practice guidelines" can be developed (& perhaps endorsed by AHRQ) for those using MEPS to report a DME/COI type study. By using & reporting all 4 methods, an analyst is giving policy-makers a range for their cost estimates. Guidelines would ensure a level of transparency in reporting such cost estimates across conditions. The ISPOR task force guidelines on good research practices for Budget Impact Analyses (BIA) identify two simultaneous processes affecting the marketplace: changes in the mix and evolution of available interventions over time (i.e., market share) and changes in the target population resulting from various disease characteristics (e.g., incidence, progression and death). In many chronic diseases, disease severity changes over time and thus medical costs vary across disease cohorts. Hence, in a budget impact model two constraints must be met: 1) the number of patients progressing from one year to the next corresponds to known disease statistics (i.e., patients who enter the model cannot be 'lost to follow-up'), 2) the total number of treated patients conforms with known population size and projected market shares. The current guidelines lack detail on how to satisfy these two constraints simultaneously in dynamic markets with non-trivial rates of patient attrition from treatment groups. OBJECTIVES: To identify a method that allows researchers to more accurately model the budget impact of new interventions for chronic diseases in dynamic markets. METHODS: We propose a simple adjustment factor which is a function of disease and treatment's attrition rate in two consecutive years to correct the allocation of patients across disease cohorts such that the two constraints identified above are always met simultaneously. We compare two settings (static vs. dynamic markets) and analyze the implications over a time period of five years. RESULTS: We find that applying the adjustment factor in dynamic markets reduces the bias in budget impact measures by 15% or more and contend that not correcting for this in more complex markets would lead to higher bias. Our proposed solution is a simple way of accounting for differential rates of attrition across treatments in a chronic disease setting in budget impact analyses.
PRM56 MODELING THE PROGRESSION OF CHRONIC DISEASES IN A DYNAMIC MARKET: IMPLICATIONS FOR BUDGET IMPACT ANALYSIS
